The Safety and Efficacy of 5-HT3 Receptor Antagonist (Ramosetron) for the Treatment of Fecal Incontinence
Status:
Not yet recruiting
Trial end date:
2024-11-01
Target enrollment:
Participant gender:
Summary
This clinical trial aims to assess the effectiveness of Ramosetron compared to Psyllium, a
gold standard therapy, in patients with fecal incontinence. The primary questions it seeks to
answer are:
1. Does Ramosetron improve the symptoms of fecal incontinence?
2. Is Ramosetron superior to Psyllium in terms of symptom improvement and its impact on
quality of life?
Participants will be randomly assigned to one of two groups, either taking Ramosetron or
Psyllium for one month. They will be asked to complete a questionnaire. Researchers will then
compare the Fecal Incontinence Severity Index between the Ramosetron and Psyllium groups to
determine whether Ramosetron provides superior symptom relief compared to Psyllium.